GoAI
Get started
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. logo

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

1541.HK

HKSEHealthcareBiotechnology

Open in GoAI

Latest quote

HK$3.41

+HK$0.02 · +0.59%

Aug 24, 4:08 PM HKT

1541.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CN
CEO
Wenzhi Tian
Listed since
Sep 5, 2023
Employees
202

Market position

Day range

Current HK$3.41

52-week range

Current HK$3.41

Open
HK$3.39
Previous close
HK$3.39
Volume
677.6K
0.53× average
Average volume
1.27M
Average daily volume
Market cap
1.43B HKD
Beta
0.22
Market reference 1
50-day average
HK$3.4816
-2.06% below average
200-day average
HK$4.7409
-28.07% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.71B CNY
P/E (TTM)
-5.52×
P/B (TTM)
1.57×
P/S (TTM)
7.77×
EV / EBITDA
-8.41×
Earnings yield
-9.86%
Free cash flow yield
-9.13%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
94.80%
Operating margin
-135.69%
Net margin
-137.35%
Return on equity
-26.89%
Return on assets
-19.38%
Return on invested capital
-21.33%

Financial health

Debt / equity
0.29×
Current ratio
3.83×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends12023%-28096%-68216%-108335%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 1993.52%Gross margin, FY2024: 100.00%Gross margin, FY2025: 89.81%Operating margin, FY2021: -1524.23%Operating margin, FY2022: -6405.13%Operating margin, FY2023: -94474.87%Operating margin, FY2024: -415.44%Operating margin, FY2025: -144.55%Net margin, FY2021: -5308.15%Net margin, FY2022: -7080.74%Net margin, FY2023: -98305.44%Net margin, FY2024: -425.97%Net margin, FY2025: -141.66%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 1993.52%. Gross margin FY2024 100.00%. Gross margin FY2025 89.81%. Operating margin FY2021 -1524.23%. Operating margin FY2022 -6405.13%. Operating margin FY2023 -94474.87%. Operating margin FY2024 -415.44%. Operating margin FY2025 -144.55%. Net margin FY2021 -5308.15%. Net margin FY2022 -7080.74%. Net margin FY2023 -98305.44%. Net margin FY2024 -425.97%. Net margin FY2025 -141.66%.

Income trends

Revenue

150.3M CNY+102.70%

Operating income

−217.26M CNY+29.47%

Net income

−212.92M CNY+32.59%
Income trends across reported periods238.63M CNY−114.67M CNY−467.97M CNY−821.27M CNYRevenue, FY2021: 13.81M CNYRevenue, FY2022: 5.69M CNYRevenue, FY2023: 386K CNYRevenue, FY2024: 74.15M CNYRevenue, FY2025: 150.3M CNYOperating income, FY2021: −210.47M CNYOperating income, FY2022: −364.45M CNYOperating income, FY2023: −364.67M CNYOperating income, FY2024: −308.04M CNYOperating income, FY2025: −217.26M CNYNet income, FY2021: −732.95M CNYNet income, FY2022: −402.89M CNYNet income, FY2023: −379.46M CNYNet income, FY2024: −315.86M CNYNet income, FY2025: −212.92M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 13.81M CNY. Revenue FY2022 5.69M CNY. Revenue FY2023 386K CNY. Revenue FY2024 74.15M CNY. Revenue FY2025 150.3M CNY. Operating income FY2021 −210.47M CNY. Operating income FY2022 −364.45M CNY. Operating income FY2023 −364.67M CNY. Operating income FY2024 −308.04M CNY. Operating income FY2025 −217.26M CNY. Net income FY2021 −732.95M CNY. Net income FY2022 −402.89M CNY. Net income FY2023 −379.46M CNY. Net income FY2024 −315.86M CNY. Net income FY2025 −212.92M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue150.3M CNY74.15M CNY386K CNY5.69M CNY13.81M CNY
Cost of goods sold15.31M CNY—−38.65K CNY——
Gross profit134.99M CNY74.15M CNY7.7M CNY5.69M CNY13.81M CNY
Research and development313.93M CNY322.76M CNY291.94M CNY277.35M CNY175.95M CNY
Selling, general, and administrative38.32M CNY64.82M CNY80.42M CNY92.8M CNY48.32M CNY
Operating expenses352.25M CNY382.19M CNY372.37M CNY370.14M CNY224.27M CNY
Interest income6.66M CNY6.38M CNY10.8M CNY9.51M CNY1.64M CNY
Interest expense5.17M CNY3.45M CNY1.52M CNY787K CNY891K CNY
Depreciation and amortization14.23M CNY12.41M CNY22.58M CNY17.62M CNY13.18M CNY
Operating income−217.26M CNY−308.04M CNY−364.67M CNY−364.45M CNY−210.47M CNY
Net income−212.92M CNY−315.86M CNY−379.46M CNY−402.89M CNY−732.95M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-0.51
FY2025
Latest fiscal-year revenue
150.3M CNY
FY2025 · +102.70% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-0.37-0.95-1.53-2.11FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend165.29M105.33M45.36M-14.61MFY21FY22FY23FY24FY25

1541.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.7

-3.94%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.46

-3.61%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.50

-2.83%

ETFs holding 1541.HK

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR Portfolio Emerging Markets ETF logoState Street SPDR Portfolio Emerging Markets ETFSPEM
Market value
314.38K
Weight
0.00%
AUM
17.57B USD
Expense ratio
0.07%
Price / 1D
$51.945-0.83%
State Street SPDR S&P Emerging Markets Small Cap ETF logoState Street SPDR S&P Emerging Markets Small Cap ETFEWX
Market value
69.38K
Weight
0.01%
AUM
685.65M USD
Expense ratio
0.65%
Price / 1D
$71.67-0.67%
State Street SPDR S&P China ETF logoState Street SPDR S&P China ETFGXC
Market value
33.22K
Weight
0.01%
AUM
474.65M USD
Expense ratio
0.59%
Price / 1D
$90.315-1.25%

Continue in GoAI

Research 1541.HK

research.disclaimer